Clinical Trial Search

Primary: Lung Function FEV1 — 84.9; 59.9 % of predicted — p=0.001

Primary: Annual Asthma Exacerbation Rate (AERR) — 0.42; 1.63 Events per year — p=<0.001

Primary: Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma — 0.93; 2.10 events per year — p=<0.001

Primary: Percent Predicted FEV1 — 58.6; 56.3 % of predicted value — p=0.745

Primary: Rate of Moderate-to-severe Asthma Exacerbations During the 52-week Treatment Period in High Eosinophils Subpopulation — 0.97; 0.77; 0.93 events/year — p=0.800

Primary: Rate of Clinically Significant Exacerbations of Asthma — 0.45; 1.31 Exacerbations per year — p=<0.001

Primary: Exhaled Nitric Oxide at Baseline and Over the Observational Period — 15.1; 9.9; 13.7; 8.6 parts per billion

Primary: Percentage of Neutrophils in Peripheral Blood — 57.3; 55.4 percentage of neutrophils — p=0.53

Primary: Rate of Moderate-to-severe Asthma Exacerbations During the 52-week Treatment Period in High Eosinophils Subpopulation — 0.73; 0.76; 1.06 Events/year — p=0.059

Primary: 16 Weeks - Juniper Asthma Quality of Life Questionnaire (AQLQ) Score — 4.7; 4.6 units on a scale

Primary: Forced Expiratory Volume in One Second (FEV1) Percent Predicted — 65.6; 66.0; 70; 69.5 percent predicted — p=0.447

Primary: Number of Participants With the Indicated Percent Reduction From Baseline in Oral Corticosteroid (OCS) Dose During Weeks 20 to 24 While Maintaining Asthma Control — 7…

Primary: Annualized Asthma Exacerbation Rate (AER) Through Week 52 — 0.72; 0.27; 0.20; 0.23 events per person-year — p=<0.001

Primary: Persistency of Response and Non-response as Based on Investigator's Global Evaluation of Treatment Effectiveness (GETE) — 190; 29; 187; 28 participants

Primary: Difference in ASM Mass Between Groups

Primary: Reduction in Rate of Asthma Exacerbations — 0.74; 0.47; 0.58; 0.42 Number of asthma exacerbations per year — p=0.0049

Primary: Mean Change From Baseline (BL) in St. George's Respiratory Questionnaire (SGRQ) Score at Week 24 — -7.9; -15.6 Scores on a scale — p=<0.001

Primary: Respiratory Adverse Events Per Subject — 9.1; 3.4; 2.6; 2.2 Respiratory Adverse Events/Subject

Primary: Number of Participants With 1 or More Severe Asthma Exacerbations — 186; 154 participants — p=0.036

Primary: Change From Baseline in the Expression of FcεRI Receptors of Blood Basophils — -84.4; 27.7 Percent change in MFI

Primary: Change From Baseline in Asthma Control Questionnaire (ACQ-7) Over 12 Weeks — -0.1; -0.2; -0.1; -0.3 Scores on Scale — p=0.1955

Primary: Change From Baseline in Pre-Dose (Trough) Pre-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1) — 0.18; 0.08 liters — p=0.013

Primary: Pairwise Comparison of Treatments Based on Composite Measure Using Treatment Failures, Asthma Control Days, and Percent Predicted FEV1. — 74; 35; 56; 12 Participants…

Primary: Airway Wall Thickness — 1.5; 1.5; 1.4; 1.6 mm — p=0.2

Primary: Number of Clinically Significant Exacerbations of Asthma Per Year — 1.74; 0.93; 0.83 Number of exacerbations per year — p=<0.001

Primary: Differences in Activity and Downstream Activity of the p38 MAPK Activity in Macrophages or PBMCs Between Those From Severe and Non-Severe Asthmatics

Primary: Number of Clinically Significant Exacerbations of Asthma Per Year — 2.40; 1.24; 1.46; 1.15 Exacerbations per year — p=<0.001

Primary: Concentration (pg/ml) of CXCL8 Cytokine in Cell Supernatant After Stimulation (IFN/TNF or IL13) and Treatment (VR588, FP or CP) Conditions in ALI Cultured Epithelial…

Primary: HAM-D (Hamilton Rating Scale for Depression) — 24.8; 28.3 units on a scale

Primary: Serum Prednisolone Levels Over 24 Hours — 800; 700; NA nmol/l